Century Therapeutics, Inc. Net Income
Century Therapeutics, Inc. (IPSC) reported Net Income of -$34.55 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-08-12
- Century Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$34.55M.
- Century Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$21.64M, a 128.27% decline year-over-year.
- Century Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$19.17M.
- Century Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$34.42M.
- Century Therapeutics, Inc. net income (loss) attributable to parent for fiscal 2025 was -$9.58M.
- Century Therapeutics, Inc. net income (loss) attributable to parent for fiscal 2024 was -$126.57M.
- Century Therapeutics, Inc. net income (loss) attributable to parent for fiscal 2023 was -$136.67M.
- Century Therapeutics, Inc. net income (loss) attributable to parent for fiscal 2022 was -$130.93M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$34.55M 10-Q · filed 2026-08-12 | -$56.20M 10-Q · filed 2026-08-12 | -$75.37M derived: sum of 3 quarters · filed 2026-08-12 | -$109.79M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$21.64M 10-Q · filed 2026-08-12 | -$40.82M derived: sum of 2 quarters · filed 2026-08-12 | -$75.24M derived: sum of 3 quarters · filed 2026-08-12 | -$107.78M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$19.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$53.59M derived: sum of 2 quarters · filed 2026-03-12 | -$86.13M derived: sum of 3 quarters · filed 2026-08-12 | -$9.58M 10-K · filed 2026-03-12 |
| 2025-09-30 | -$34.42M 10-Q · filed 2025-11-13 | -$66.96M derived: sum of 2 quarters · filed 2026-08-12 | $9.59M 10-Q · filed 2025-11-13 | -$26.48M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$32.54M 10-Q · filed 2026-08-12 | $44.02M 10-Q · filed 2026-08-12 | $7.95M derived: sum of 3 quarters · filed 2026-08-12 | -$23.28M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $76.56M 10-Q · filed 2026-08-12 | $40.49M derived: sum of 2 quarters · filed 2026-08-12 | $9.26M derived: sum of 3 quarters · filed 2026-08-12 | -$21.95M derived: sum of 4 quarters · filed 2026-08-12 |
| 2024-12-31 | -$36.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$67.30M derived: sum of 2 quarters · filed 2026-03-12 | -$98.51M derived: sum of 3 quarters · filed 2026-03-12 | -$126.57M 10-K · filed 2026-03-12 |
| 2024-09-30 | -$31.23M 10-Q · filed 2025-11-13 | -$62.43M derived: sum of 2 quarters · filed 2025-11-13 | -$90.49M 10-Q · filed 2025-11-13 | -$129.89M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$31.21M 10-Q · filed 2025-11-13 | -$59.27M 10-Q · filed 2025-08-14 | -$98.67M derived: sum of 3 quarters · filed 2025-11-13 | -$131.39M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-03-31 | -$28.06M 10-Q · filed 2025-11-13 | -$67.46M derived: sum of 2 quarters · filed 2025-11-13 | -$100.18M derived: sum of 3 quarters · filed 2025-11-13 | -$133.47M derived: sum of 4 quarters · filed 2025-11-13 |
| 2023-12-31 | -$39.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | -$72.12M derived: sum of 2 quarters · filed 2025-03-19 | -$105.41M derived: sum of 3 quarters · filed 2025-03-19 | -$136.67M 10-K · filed 2025-03-19 |
| 2023-09-30 | -$32.72M 10-Q · filed 2024-11-05 | -$66.01M derived: sum of 2 quarters · filed 2024-11-05 | -$97.28M 10-Q · filed 2024-11-05 | -$128.96M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | -$33.29M 10-Q · filed 2024-11-05 | -$64.56M 10-Q · filed 2024-08-08 | -$96.24M derived: sum of 3 quarters · filed 2024-11-05 | -$126.99M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-03-31 | -$31.26M 10-Q · filed 2024-11-05 | -$62.95M derived: sum of 2 quarters · filed 2024-11-05 | -$93.69M derived: sum of 3 quarters · filed 2024-11-05 | -$124.68M derived: sum of 4 quarters · filed 2024-11-05 |
| 2022-12-31 | -$31.68M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$62.43M derived: sum of 2 quarters · filed 2024-03-14 | -$93.42M derived: sum of 3 quarters · filed 2024-03-14 | -$130.93M 10-K · filed 2024-03-14 |
| 2022-09-30 | -$30.75M 10-Q · filed 2023-11-09 | -$61.74M derived: sum of 2 quarters · filed 2023-11-09 | -$99.25M 10-Q · filed 2023-11-09 | -$127.44M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$30.99M 10-Q · filed 2023-11-09 | -$68.50M 10-Q · filed 2023-08-09 | -$96.69M derived: sum of 3 quarters · filed 2023-11-09 | -$122.70M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-03-31 | -$37.51M 10-Q · filed 2023-11-09 | -$65.71M derived: sum of 2 quarters · filed 2023-11-09 | -$91.72M derived: sum of 3 quarters · filed 2023-11-09 | -$114.99M derived: sum of 4 quarters · filed 2023-11-09 |
| 2021-12-31 | -$28.19M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | -$54.20M derived: sum of 2 quarters · filed 2023-03-16 | -$77.48M derived: sum of 3 quarters · filed 2023-03-16 | -$95.82M 10-K · filed 2023-03-16 |
| 2021-09-30 | -$26.01M 10-Q · filed 2022-11-10 | -$49.28M derived: sum of 2 quarters · filed 2022-11-10 | -$67.63M 10-Q · filed 2022-11-10 | -$83.16M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$23.27M 10-Q · filed 2022-11-10 | -$41.62M 10-Q · filed 2022-08-11 | -$57.15M derived: sum of 3 quarters · filed 2022-11-10 | -$70.22M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-03-31 | -$18.35M 10-Q · filed 2022-11-10 | -$33.88M derived: sum of 2 quarters · filed 2022-11-10 | -$46.95M derived: sum of 3 quarters · filed 2022-11-10 | -$62.25M derived: sum of 4 quarters · filed 2022-11-10 |
| 2020-12-31 | -$15.53M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | -$28.60M derived: sum of 2 quarters · filed 2022-03-17 | -$43.90M derived: sum of 3 quarters · filed 2022-03-17 | -$53.58M 10-K · filed 2022-03-17 |
| 2020-09-30 | -$13.07M 10-Q · filed 2021-11-10 | -$28.37M derived: sum of 2 quarters · filed 2021-11-10 | -$38.04M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$15.30M 10-Q · filed 2021-11-10 | -$24.97M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | -$9.67M 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |